CTOs on the Move

Humacyte

www.humacyte.com

 
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.humacyte.com
  • 2525 E NC Highway 54
    Durham, NC USA 27713
  • Phone: 919.313.9633

Executives

Name Title Contact Details
Heather Prichard
 Chief Operating Officer Profile

Funding

Humacyte raised $150M on 10/20/2015
Humacyte raised $18M on 10/02/2017
Humacyte raised $150M on 06/11/2018
Humacyte raised $50M on 04/14/2021
Humacyte raised $38M on 04/14/2021

Similar Companies

LaZure Scientific

LaZure Scientific is a Issaquah, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ENGAGE Healthcare Business Services

ENGAGE Healthcare Business Services is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProTrials Research

ProTrials Research is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wabash County Hospital

Wabash County Hospital is a county-owned, critical access hospital. With 25 inpatient beds, we offer critical care services, emergency services, cancer treatment and much more.

Relievant Medsystems

Relievant Medsystems, Inc., a privately held medical device company pioneering the INTRACEPT therapy of nerve ablation within vertebral bodies for the treatment of chronic low back pain (CLBP). The INTRACEPT Intraosseous Nerve Ablation System is a patent-protected, minimally invasive, implant-free therapy that utilizes radiofrequency energy delivered into the vertebral body of the spine to ablate the Basivertebral Nerve (BVN). This nerve, characterized in peer-reviewed literature reporting studies of pain signal transmission and in preclinical and clinical evaluations, is a significant contributor in the transduction of pain arising from degeneration of the vertebral bodies associated with CLBP. The INTRACEPT Intraosseous Nerve Ablation System leverages proprietary instruments and methods to disable this nerve.